Product Identification

Product Name

2-Mercapto-6-propylpyrimid-4-one

Synonyms

2,3-Dihydro-6-propyl-2-thioxo-4(1h)pyrimidinone
2-Mercapto-4-hydroxy-6-n-propylpyrimidine
2-Mercapto-6-propylpyrimid-4-one
Procasil
Propacil
Propycil

CAS

51-52-5

Formula

C7H10N2OS

Molecular Weight

170.23

EINECS

200-103-2

RTECS

YR1400000

RTECS Class

Tumorigen; Drug; Mutagen; Reproductive Effector; Human Data

Merck

12,8054

Beilstein/Gmelin

130039

Beilstein Reference

5-24-07-00257

EC Class

harmful

Physical and Chemical Properties

Appearance

Odorless white crystalline powder of starch-like appearance. Bitter taste. Saturated solution is neutral or slightly acid to litmus.

Solubility in water

Slightly soluble

Melting Point

215 - 218

Boiling Point

448

Vapor Pressure

0.54 (25 C)

pKa/pKb

7.63 (pKa)

Partition Coefficient

1.37

Usage

Medication.

First Aid Measures

Ingestion

If victim is conscious and alert, give 2-4 cupfuls of milk or water. Get medical aid immediately.

Inhalation

Get medical aid immediately. Remove from exposure to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Skin

Get medical aid. Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes. Remove contaminated clothing and shoes.

Eyes

Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.

Handling and Storage

Storage

Store in a cool, dry place. Keep container closed when not in use. Hormones and antibiotics room.

Handling

Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation.

Hazards Identification

Ingestion

See inhalation.

Inhalation

Symptoms of exposure to this compound include recurrent painful skin lesions, fatigue, migratory polyanthralgias of hands and knees, palpable spleen, splenomegaly, amenorrhea, low-grade fever, gingivostomatitis, weakness, weight loss, dark red-brown colored urine, necrotizing vasculitis, leukopenia, cutaneous vasculitis, nasal congestion, enlarged thyroid, necrotic ulcerations on the lower extremities, bloody nasal discharge and cough.

Skin

Skin rashes may occur secondary to hematologic toxicity during chronic therapy.

Eyes

See inhalation

EC Risk Phrase

R 22

EC Safety Phrase

S 24/25

Exposure Controls/Personal Protection

Personal Protection

Eyes: Wear chemical goggles. Skin: Wear appropriate protective gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to minimize contact with skin.

Respirators

A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant a respirator's use.

Fire Fighting Measures

Fire Fighting

Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Extinguishing media: Use agent most appropriate to extinguish fire.

Accidental Release Measures

Small spills/leaks

Clean up spills immediately, using the appropriate protective equipment.

Stability and Reactivity

Incompatibilities

Incompatible with strong oxidizing agents, strong acids and strong bases Reacts with sulfhydryl-oxidizing agents.

Stability

Stable under normal temperatures and pressures.

Decomposition

Irritating and toxic fumes and gases.

Transport Information

HS Code

2933 59 95